Moreover, CDK7 inhibition has been shown to be effective in low concentrations in many cancer types, including leukemia [19], ovarian cancer [40], and colon cancer [41], which makes CDK7 inhibitors good candidates for use as adjuvant breast cancer treatment. This evidence concerns the gene CDK7 and ovarian cancer.